S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Palo Alto Networks aims at cyber security leadership
3 Reasons the Capital One-Discover merger is a big deal
Is Gold Really Boring? (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Germany says Europe's largest economy is in 'troubled waters' and cuts its growth forecast
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Teladoc Health gaps down to support level after weak guidance
Housing data weakens, but Toll Brothers stock is still a buy
S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Palo Alto Networks aims at cyber security leadership
3 Reasons the Capital One-Discover merger is a big deal
Is Gold Really Boring? (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Germany says Europe's largest economy is in 'troubled waters' and cuts its growth forecast
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Teladoc Health gaps down to support level after weak guidance
Housing data weakens, but Toll Brothers stock is still a buy
S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Palo Alto Networks aims at cyber security leadership
3 Reasons the Capital One-Discover merger is a big deal
Is Gold Really Boring? (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Germany says Europe's largest economy is in 'troubled waters' and cuts its growth forecast
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Teladoc Health gaps down to support level after weak guidance
Housing data weakens, but Toll Brothers stock is still a buy
S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Palo Alto Networks aims at cyber security leadership
3 Reasons the Capital One-Discover merger is a big deal
Is Gold Really Boring? (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Germany says Europe's largest economy is in 'troubled waters' and cuts its growth forecast
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Teladoc Health gaps down to support level after weak guidance
Housing data weakens, but Toll Brothers stock is still a buy
NASDAQ:PMVP

PMV Pharmaceuticals (PMVP) Stock Price, News & Analysis

$1.69
+0.09 (+5.63%)
(As of 02/21/2024 ET)
Today's Range
$1.59
$1.70
50-Day Range
$1.51
$3.26
52-Week Range
$1.18
$9.72
Volume
396,789 shs
Average Volume
513,828 shs
Market Capitalization
$86.46 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.00

PMV Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
432.5% Upside
$9.00 Price Target
Short Interest
Healthy
4.75% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Selling Shares
$195,763 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.52) to ($1.75) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.49 out of 5 stars

Medical Sector

717th out of 932 stocks

Pharmaceutical Preparations Industry

342nd out of 431 stocks


PMVP stock logo

About PMV Pharmaceuticals Stock (NASDAQ:PMVP)

PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. It is also developing Wild-type p53 or other p53 mutations, including R273H, R273C, R175H, G245S, R248Q, and R282W, as well as other p53 hotspot mutations. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Cranbury, New Jersey.

PMVP Stock Price History

PMVP Stock News Headlines

Gold Could Be Heading for Record Highs - But How to Play It?
According to FX Empire, the gold forecast is now bullish, with support for a $3,000 target in 2024. The big question is how to play it. Some investors are discovering a unique gold investment alternative that sidesteps the major issues with gold mining stocks or physical gold.
Is Gold Really Boring?
Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.
See More Headlines
Receive PMVP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PMV Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/12/2021
Today
2/22/2024
Next Earnings (Estimated)
3/06/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:PMVP
Fax
N/A
Employees
62
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$9.00
High Stock Price Target
$15.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+432.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-73,320,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$5.39 per share

Miscellaneous

Free Float
47,270,000
Market Cap
$86.46 million
Optionable
Optionable
Beta
1.65
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Dr. David H. Mack Ph.D. (Age 62)
    Co-Founder, CEO, President & Director
    Comp: $762.02k
  • Dr. Arnold J. Levine Ph.D. (Age 84)
    Co-Founder, Director & Member of Scientific Advisory Board
    Comp: $140k
  • Mr. Winston Kung M.B.A.Mr. Winston Kung M.B.A. (Age 48)
    Advisor
    Comp: $591.29k
  • Dr. Leila Alland M.D. (Age 61)
    Advisor
    Comp: $601.93k
  • Dr. Thomas E. Shenk Ph.D. (Age 77)
    Co-Founder & Member of Scientific Advisory Board
  • Mr. Michael Carulli
    Chief Financial Officer
  • Mr. Robert Ticktin (Age 62)
    General Counsel, Head of Operations & Company Secretary
  • Mr. Tim Smith
    Senior VP & Head of Corporate Development and Investor Relations
  • Ms. Crystal Zuckerman
    Vice President of Human Resources
  • Dr. Binh Vu Ph.D.
    Senior VP of Drug Discovery & CMC














PMVP Stock Analysis - Frequently Asked Questions

Should I buy or sell PMV Pharmaceuticals stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for PMV Pharmaceuticals in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PMVP shares.
View PMVP analyst ratings
or view top-rated stocks.

What is PMV Pharmaceuticals' stock price target for 2024?

3 Wall Street analysts have issued 12-month price objectives for PMV Pharmaceuticals' stock. Their PMVP share price targets range from $5.00 to $15.00. On average, they predict the company's stock price to reach $9.00 in the next year. This suggests a possible upside of 432.5% from the stock's current price.
View analysts price targets for PMVP
or view top-rated stocks among Wall Street analysts.

How have PMVP shares performed in 2024?

PMV Pharmaceuticals' stock was trading at $3.10 at the start of the year. Since then, PMVP shares have decreased by 45.5% and is now trading at $1.69.
View the best growth stocks for 2024 here
.

Are investors shorting PMV Pharmaceuticals?

PMV Pharmaceuticals saw a increase in short interest in the month of January. As of January 31st, there was short interest totaling 1,750,000 shares, an increase of 12.9% from the January 15th total of 1,550,000 shares. Based on an average daily trading volume, of 464,000 shares, the days-to-cover ratio is currently 3.8 days. Approximately 4.8% of the shares of the company are short sold.
View PMV Pharmaceuticals' Short Interest
.

When is PMV Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 6th 2024.
View our PMVP earnings forecast
.

How were PMV Pharmaceuticals' earnings last quarter?

PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) announced its quarterly earnings results on Friday, November, 12th. The company reported ($0.33) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by $0.03.

What ETFs hold PMV Pharmaceuticals' stock?

ETFs with the largest weight of PMV Pharmaceuticals (NASDAQ:PMVP) stock in their portfolio include Virtus LifeSci Biotech Clinical Trials ETF (BBC).IQ Chaikin U.S. Small Cap ETF (CSML).

What other stocks do shareholders of PMV Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PMV Pharmaceuticals investors own include Vical (VICL), Arista Networks (ANET), Apollo Medical (AMEH), Advanced Micro Devices (AMD), Ambarella (AMBA), Alexion Pharmaceuticals (ALXN), Akoustis Technologies (AKTS), Agios Pharmaceuticals (AGIO), Admiral Group (ADM) and Adobe (ADBE).

When did PMV Pharmaceuticals IPO?

(PMVP) raised $126 million in an IPO on Friday, September 25th 2020. The company issued 7,400,000 shares at $16.00-$18.00 per share. Goldman Sachs, BofA Securities, Cowen and Evercore ISI acted as the underwriters for the IPO.

Who are PMV Pharmaceuticals' major shareholders?

PMV Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (4.70%), Verition Fund Management LLC (3.09%), PFM Health Sciences LP (2.88%), Goldman Sachs Group Inc. (1.57%), Point72 Asset Management L.P. (1.47%) and Federated Hermes Inc. (1.37%). Insiders that own company stock include Arnold J Levine, Arnold J Levine, David Henry Mack, Deepika Jalota, Euclidean Capital Llc, Laszlo Kopits, Leila Alland, Ling Zang, Orbimed Advisors Llc, Paul Klauder, Richard A Heyman, Thilo Schroeder and Winston Kung.
View institutional ownership trends
.

How do I buy shares of PMV Pharmaceuticals?

Shares of PMVP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PMVP) was last updated on 2/22/2024 by MarketBeat.com Staff